Quoin Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, has announced its financial results for the third quarter of 2026, marking a significant milestone in its ongoing efforts to develop treatments for rare diseases.
On November 5, 2026, Quoin reported positive interim data from its Phase 2/3 study of QRX003, a treatment for Netherton Syndrome. The company achieved statistical significance for both the primary and key secondary endpoints, which is a notable achievement in a field that has seen limited progress.
Dr. Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals, expressed optimism about the company's future, stating, "The third quarter substantially strengthened Quoin’s clinical, regulatory and financial foundation for long-term growth." He highlighted the importance of the interim results, which he believes represent the first overall positive data set published for Netherton Syndrome.
Quoin also announced a private placement financing of up to $50 million with healthcare-focused institutional investors, which will provide the necessary funding to advance its clinical programs. This includes the completion of the development of QRX003 for Netherton Syndrome and investments in other pipeline products.
Background
Quoin Pharmaceuticals Ltd. operates within the pharmaceutical preparations sector (SIC 2834) and is listed on the Nasdaq under the ticker symbol QNRX. The company focuses on developing treatments for rare and orphan diseases, positioning itself as a key player in this niche market.
Recent filings indicate that Quoin has been active in the market, with a series of reports leading up to this latest announcement. The company filed an 8-K on November 6, 2026, detailing its financial results and corporate updates.
What the Filing Says
The filing reveals that on November 5, 2026, Quoin Pharmaceuticals issued a press release announcing its financial results for the quarter ended September 30, 2026. The press release, which is included as Exhibit 99.1 in the filing, highlights several key achievements, including:
- Positive interim data from the Phase 2/3 study of QRX003 in Netherton Syndrome.
- FDA clearance of the first-ever IND for Peeling Skin Syndrome (PSS).
- Granting of Rare Pediatric Disease and Fast Track designations for QRX003.
- A successful private placement financing of up to $50 million.
Impact
This update from Quoin Pharmaceuticals may significantly affect various stakeholders, including investors, healthcare professionals, and patients suffering from rare diseases. The positive trial results for QRX003 could lead to increased investor confidence and support for the company's ongoing research efforts.
Moreover, the financing announcement indicates a strong commitment to advancing its clinical programs, which could enhance the company's competitive position in the pharmaceutical preparations industry.
What's Next
Looking ahead, Quoin Pharmaceuticals aims to complete recruitment for its Netherton Syndrome study by the end of 2026 and plans to report topline data in the second quarter of 2027. Additionally, the company is set to initiate the first formal clinical study in Peeling Skin Syndrome before the year ends. These developments will be closely monitored by stakeholders as they unfold.
For further details, the full filing can be accessed through the SEC's website under accession number 0001104659-26-123960.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










